BPC-157 + TB-500 Blend
ALSO SOLD AS Wolverine blend · Wolverine
See the stack breakdown →Last reviewed 2026-10-30
Our read Opinion
No controlled blend trials were found. A retrospective knee-pain series included four BPC-157 plus TB4 recipients; it does not verify the marketed TB-500 fragment or pre-mixed product.
- Type
- Research-only / unapproved
- Regulatory status
- No FDA approval for the blend
- Compounding status
- Not allowed (blends excluded)
- FDA-approved indications
- None
- Evidence level
- Animal studies mostly
- Routes studied
- —
- WADA
- Prohibited
- Developer
- —
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Claimed to speed recovery from tendon, ligament, muscle and joint injuries
- —Claimed to lower inflammation
BPC-157 has preclinical tissue-repair findings; thymosin-beta-4 biology involves actin binding and cell migration. Full-length thymosin-beta-4 findings cannot establish effects of the TB-500 fragment.
Not a peptide: a pre-mixed blend of BPC-157 + TB-500 ("Wolverine"). Neither component is FDA-approved; FDA flags limited safety information for BPC-157 and no human exposure data for the TB-500 fragment.
Statuses change; check the linked primary source.
Momentum Opinion
Watch
0 news items in last 30 days
The Wolverine name is not evidence of faster recovery. A tiny uncontrolled TB4 combination report does not establish this blend’s efficacy or safety.
No news yet for this peptide.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.